Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,512.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $235.42, for a total transaction of $847,512.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,604.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR opened at $235.31 on Thursday. United Therapeutics Co. has a one year low of $204.44 and a one year high of $261.54. The stock has a 50-day moving average of $230.70 and a 200 day moving average of $228.38. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of 11.86 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The firm had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. During the same quarter last year, the firm posted $2.67 EPS. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics Co. will post 23.46 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Finally, HC Wainwright reissued a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $292.67.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. DekaBank Deutsche Girozentrale lifted its holdings in shares of United Therapeutics by 54.4% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock valued at $20,617,000 after buying an additional 33,338 shares during the period. Nordea Investment Management AB grew its stake in shares of United Therapeutics by 155.2% during the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after purchasing an additional 23,532 shares during the period. Louisiana State Employees Retirement System bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $2,903,000. O Shaughnessy Asset Management LLC increased its position in shares of United Therapeutics by 4.9% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 107 shares during the last quarter. Finally, DnB Asset Management AS bought a new position in shares of United Therapeutics in the 3rd quarter worth approximately $3,340,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.